Shujun Fu

920 total citations
36 papers, 648 citations indexed

About

Shujun Fu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shujun Fu has authored 36 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 14 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Shujun Fu's work include Cancer, Hypoxia, and Metabolism (6 papers), Cancer-related Molecular Pathways (5 papers) and Cancer, Lipids, and Metabolism (4 papers). Shujun Fu is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), Cancer-related Molecular Pathways (5 papers) and Cancer, Lipids, and Metabolism (4 papers). Shujun Fu collaborates with scholars based in China, United States and France. Shujun Fu's co-authors include Xiyun Deng, Ying Li, Lunquan Sun, Zhijun Zhan, Guangchun He, Chanjuan Zheng, Huimei Yi, Wenfeng Hu, Rong Tan and Lu Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biochemical and Biophysical Research Communications and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Shujun Fu

35 papers receiving 644 citations

Peers

Shujun Fu
Shujun Fu
Citations per year, relative to Shujun Fu Shujun Fu (= 1×) peers Carlos Martínez-Pérez

Countries citing papers authored by Shujun Fu

Since Specialization
Citations

This map shows the geographic impact of Shujun Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shujun Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shujun Fu more than expected).

Fields of papers citing papers by Shujun Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shujun Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shujun Fu. The network helps show where Shujun Fu may publish in the future.

Co-authorship network of co-authors of Shujun Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Shujun Fu. A scholar is included among the top collaborators of Shujun Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shujun Fu. Shujun Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Zhiyu, Yuxuan Guo, Xinyu Wang, et al.. (2025). Inducing ferroptosis in breast cancer with nanoparticles: a promising and challenging therapeutic strategy. Journal of Materials Chemistry B. 13(42). 13567–13588. 1 indexed citations
2.
Luo, Huaiqing, et al.. (2025). Role of Achyranthes aspera in neurodegenerative diseases: current evidence and future directions. Frontiers in Pharmacology. 16. 1511011–1511011. 3 indexed citations
3.
Guo, Yuxuan, Da Huang, Jing Yang, et al.. (2025). Dual roles of GM-CSF in breast cancer: Immunomodulation and therapeutic implications. Critical Reviews in Oncology/Hematology. 214. 104804–104804. 1 indexed citations
4.
Wang, Zhiyu, Xinyu Wang, Da Wei Huang, et al.. (2024). Unlocking the Hidden Potential of Cancer Therapy Targeting Lysine Succinylation. Journal of Cancer. 16(3). 821–834. 1 indexed citations
5.
Zhu, Jianyu, Muyao Wu, Lian Xue, et al.. (2023). Amino acids and their roles in tumor immunotherapy of breast cancer. The Journal of Gene Medicine. 26(1). e3647–e3647. 2 indexed citations
6.
Zheng, Chanjuan, Muyao Wu, Lian Xue, et al.. (2023). Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance. Breast Cancer Research. 25(1). 88–88. 30 indexed citations
7.
Chen, Sisi, Ying Li, Muyao Wu, et al.. (2022). Nucleolar and Coiled-Body Phosphoprotein 1 Is Associated With Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer. Frontiers in Oncology. 12. 731528–731528. 8 indexed citations
8.
Xue, Lian, Ying Li, Muyao Wu, et al.. (2022). Hexokinase 2 Is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells. Journal of Cancer. 13(12). 3368–3377. 7 indexed citations
9.
Hu, Zhe-Yu, Chanjuan Zheng, Jianbo Yang, et al.. (2022). Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer. Frontiers in Oncology. 12. 804466–804466. 12 indexed citations
10.
Li, Ying, Jianyu Zhu, Chanjuan Zheng, et al.. (2021). Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8. Biochemical and Biophysical Research Communications. 589. 85–91. 16 indexed citations
11.
Zhang, Qiuting, Huimei Yi, Hui Yao, et al.. (2021). Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis. Journal of Cancer. 12(13). 4075–4085. 99 indexed citations
12.
Li, Ying, et al.. (2021). Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. Frontiers in Oncology. 11. 731535–731535. 86 indexed citations
13.
Yi, Huimei, Ying Li, Yuan Tan, et al.. (2021). Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives. Frontiers in Oncology. 11. 648139–648139. 24 indexed citations
14.
Yan, Shichao, Zhangyong Hong, Jing Wang, et al.. (2020). CD133 peptide-conjugated pyropheophorbide-a as a novel photosensitizer for targeted photodynamic therapy in colorectal cancer stem cells. Biomaterials Science. 9(6). 2020–2031. 17 indexed citations
15.
Thein, Kyaw Zin, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, et al.. (2020). 565P Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Annals of Oncology. 31. S486–S486. 1 indexed citations
16.
Li, Zhi, Junju He, Shujun Fu, et al.. (2019). Epstein–Barr virus noncoding RNAs from the extracellular vesicles of nasopharyngeal carcinoma (NPC) cells promote angiogenesis via TLR3/RIG-I-mediated VCAM-1 expression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1865(6). 1201–1213. 38 indexed citations
17.
Fu, Shujun, et al.. (2014). Identification of pork in meat products using real-time loop-mediated isothermal amplification. Biotechnology & Biotechnological Equipment. 28(5). 882–888. 40 indexed citations
18.
Qiu, Feng, et al.. (2012). LC–ESI-MS/MS analysis and pharmacokinetics of 6′-hydroxy justicidin A, a potential antitumor active component isolated from Justicia procumbens, in rats. Journal of Pharmaceutical and Biomedical Analysis. 70. 539–543. 9 indexed citations
20.
Si, Luqin, et al.. (2006). High performance liquid chromatographic determination MELE concentration and the binding rate of MELE to human plasma proteins. Chinese Journal of Hospital Pharmacy. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026